BPC-157 is a gastric pentadecapeptide that has been found to have positive effects on growth hormones and healing properties in various medical conditions such as spinal cord injury and burn wounds.
In a study involving rats, BPC-157 was administered in doses of 0, 0.1, 0.25, and 0.5 micrograms/mL over 24 hours. Results showed that the 0.5 microgram/mL dose significantly increased growth hormone expression from day 1 to day 3, while lower doses also had similar effects. The study concluded that BPC-157 supplementation led to increased up-regulation of growth hormone in a dose and time-dependent manner.
Researchers are unsure of the exact process of how BPC-157 facilitates healing, but real-time PCR, Western Blot Analysis, and MTT assay showed increased healing and growth in tendon fibroblasts of rats treated with BPC-157.
In a separate study, BPC-157 was injected into spinal cord lesions of rats, resulting in increased motor function and rescue in the tail compared to rats injected with saline. Similar effects were observed with neural stem cell or bone marrow stromal cell injections.
The study also found that BPC-157 had beneficial effects on muscle function, counteracting the negative effects of inflammatory cytokines associated with various types of trauma. This suggests that BPC-157 could facilitate healing in various other muscular injuries that would not normally heal on their own.
The primary concern for peptide researchers today is product purity. Nord-sci guarantees our product purity by performing independent testing of our products and providing those certifications for our customers in our product descriptions.
THIS PRODUCT IS NOT INTENDED TO TREAT, CURE OR DIAGNOSE ANY CONDITION OR DISEASE AND IS NOT FOR HUMAN CONSUMPTION. ALL PRODUCTS OFFERED ARE INTENDED FOR LABORATORY RESEARCH USE ONLY.
When purchasing BPC 157 online, it's crucial to select reputable suppliers. Look for vendors with positive reviews, like Nordsci, and transparent business practices. Some online platforms specialize in peptide therapy products, offering a range of options including integrative peptides for various health concerns. We can help in many different ways, and please check out our full list of products.
Product specifications are vital when buying BPC 157. Ensure the supplier provides detailed information about the peptide's purity and concentration.
Also, consider the form of the peptide. BPC 157 is available in different forms. Understanding these options will help you make an informed purchase decision. See our blog on BPC 157 for more information.
BPC-157 cost varies depending on several factors. On average, research-grade BPC 157 prices range from $60 to $150 per vial. Factors influencing the price include purity, concentration, supplier reputation, and form (powder or pre-mixed).
Suppliers may price their products differently based on their sourcing and quality control measures. Understanding why prices vary can help you make a cost-effective choice without compromising quality.
Research-grade BPC 157 typically costs between $50 and $150 or more per vial. This range reflects the quality and purity necessary for effective results, typically.
Prices vary due to differences in production processes, quality control, and supplier overheads. Suppliers who invest in high-quality manufacturing and rigorous testing will incur higher costs, which reflect in their pricing.
All products are produced using lyophilization (freeze-drying), a preservation method that allows peptides to remain fully stable during shipping for approximately 3-4 months. Once a peptide has been reconstituted with bacteriostatic water, it must be refrigerated to maintain integrity. After reconstitution, peptides typically remain stable for up to 30 days when stored properly.
Lyophilization, also referred to as cryodesiccation, is a specialized dehydration process in which peptides are first frozen and then exposed to a low-pressure environment. This causes the water within the vial to transition directly from a solid to a vapor (sublimation), leaving behind a dry, crystalline white material known as a lyophilized peptide. In this powdered form, peptides may be safely stored at room temperature until they are ready to be reconstituted with bacteriostatic water.
After delivery, peptides should be protected from heat and light. If use is expected within the near future (whether days, weeks, or a few months) refrigerated storage below 4°C (39°F) is generally sufficient. Lyophilized peptides are commonly stable at room temperature for several weeks or longer, making short-term ambient storage acceptable when use is anticipated within that timeframe.
For extended storage, ranging from several months to multiple years, freezing is strongly recommended. Storage at -80°C (-112°F) offers optimal long-term stability and helps preserve peptide structure and quality over time.
For more detailed guidance on peptide handling and storage best practices, please refer to the resource below:
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide fragment derived from a naturally occurring gastric protein. In preclinical research, this peptide has been investigated for its potential to support mucosal integrity, tissue repair, and vascular remodeling in a variety of experimental models.
Studies in cell culture and animal systems suggest that BPC-157 may interact with multiple biological pathways involved in wound closure, angiogenesis, nitric oxide signaling, and protection against drug-induced tissue injury. Nordsci supplies BPC-157 as a high-purity research peptide, manufactured via chemical synthesis and designated strictly for controlled laboratory use.
BPC-157 is a laboratory-synthesized derivative of a larger body protection compound found in the human digestive tract. Native BPC is thought to contribute to the protection and maintenance of the gastrointestinal lining, helping preserve barrier function in the presence of gastric acid, bile, and other digestive factors.
The isolated BPC-157 fragment contains 15 amino acids yet retains many of the functional properties of the parent protein in preclinical models. Experimental work has associated BPC-157 with effects on:
BPC-157 is a pentadecapeptide with the following structural characteristics:
Sequence: Gly- Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
Molecular Formula: C62H98N16O22
Molecular Weight: 1419.556 g/mol
PubChem CID: 108101
Source: PubChem
The endogenous body protection compound in the GI tract is believed to support the mucosal barrier that shields underlying tissues from gastric acid, bile, and other digestive contents. In vitro and in vivo work indicates that BPC-157 can enhance fibroblast proliferation and migration in a dose-dependent fashion, both in culture and in animal models.[1]
Fibroblasts are central to wound repair because they synthesize extracellular matrix proteins such as collagen, fibrin, and elastin. By accelerating fibroblast recruitment and outgrowth, BPC-157 provides a useful research tool for modeling faster wound closure and mucosal healing under controlled laboratory conditions.
BPC-157 has been described as a potent pro-angiogenic factor, with data showing increased endothelial cell proliferation and growth in experimental systems.[1]–[3] Rodent models demonstrate that BPC-157 can markedly increase collateral vessel formation in settings of ischemia and venous occlusion, helping restore blood flow to downstream tissues.[4]
Although much of the work has focused on the GI tract, additional studies suggest comparable vascular support in cardiovascular, neurologic, and skeletal muscle tissues, raising interest in BPC-157 as a model compound for studying post-ischemic recovery.[5], [6] Chicken embryo work indicates that these angiogenic effects may be mediated, at least in part, through stimulation of VEGFR2 within nitric oxide–linked signaling pathways.[4], [7], [8]
BPC-157 concentration versus vascular endothelial cell growth
Source: PubMed
Cell culture research has described “vascular running” following BPC-157 exposure – the process by which new blood vessels extend toward injured tissue or around blocked vessels to re-establish perfusion.[9] This line of investigation is being used to explore strategies for managing slow-progressing arterial occlusions in preclinical models.
Because BPC-157 appears to support both fibroblast activity and microvascular growth, it has been evaluated extensively in tendon, ligament, bone, and other connective tissue models. These tissues are characteristically slow to heal due to limited baseline blood supply, which restricts the arrival of repair cells and nutrients.
In vitro and in vivo experiments in rat tendons show that BPC-157 can enhance collateralization, increase fibroblast density, and promote tendon outgrowth in injured regions. Comparative research suggests that BPC-157 may outperform standard angiogenic growth factors such as bFGF, EGF, and VEGF in specific connective tissue healing assays.[10]
FITC-phalloidin staining indicates that BPC-157 is a strong stimulator of F-actin formation in fibroblasts, consistent with enhanced cell migration and structural integrity.[11] Western blot analysis further suggests increased phosphorylation of paxillin and FAK, two proteins central to focal adhesion dynamics and directed cell movement.[12]
Rodent studies highlight a potential role for BPC-157 in modulating oxidative stress. The peptide has been reported to neutralize certain nitric oxide–related markers and reduce levels of malondialdehyde (MDA), a common indicator of lipid peroxidation.[3]
Further work in GI models shows reduced reactive oxygen species production in the presence of BPC-157. Engineered Lactococcus lactis expressing BPC-157 has been used to markedly elevate peptide levels in GI cell culture, enabling additional study of antioxidant and cytoprotective mechanisms.[13]
Another major research focus is the ability of BPC-157 to counteract specific drug-induced side effects in animal models. NSAIDs such as ibuprofen and celecoxib are limited by GI and cardiovascular toxicity, and psychotropic medications can drive serious neurologic and cardiac adverse events.
Celecoxib-induced gastric lesions (black) in rats treated with BPC-157, saline (control), L-NAME, and L-arginine.
Source: World Journal of Gastroenterology
Preclinical work indicates that BPC-157 can mitigate GI, liver, and brain lesions associated with NSAID exposure, while also blunting QTc prolongation caused by a range of antipsychotics and antiemetics.[6], [14]
Additional studies show that BPC-157 can reduce severe neurologic side effects such as catalepsy and somatosensory disturbance induced by neuroleptics, offering a platform for exploring strategies to separate therapeutic effects from limiting toxicities in experimental models.[15]
Beyond mammalian research, BPC-157 has been tested in honeybee models relevant to colony collapse disorder (CCD). Infection of honeybee GI tracts by the fungus Nosema ceranae has been implicated in rapid colony decline.
Field trials in which honeybee feed was supplemented with BPC-157 demonstrated reduced intestinal damage and improved hive survival metrics under apiary conditions.[16] This work underscores the breadth of experimental systems in which BPC-157 can be deployed as a research tool.
BPC-157 continues to be evaluated across a wide range of cell culture and animal models. Current investigations focus not only on its potential to support wound healing and vascular growth, but also on its value as a probe for understanding the regulation of angiogenesis, ischemia–reperfusion injury, oxidative stress, and drug–tissue interactions.
The peptide has shown favorable experimental tolerability profiles in rodent studies, with both oral and subcutaneous routes explored. However, per-kilogram dosing in animals does not scale to humans and is not intended to inform clinical use. BPC-157 offered by Nordsci is limited to educational and scientific research purposes and is not approved for human or veterinary administration.
THIS PRODUCT IS INTENDED FOR LABORATORY RESEARCH USE ONLY. NOT FOR HUMAN CONSUMPTION. NOT INTENDED TO DIAGNOSE, TREAT, CURE, OR PREVENT ANY DISEASE OR CONDITION.
The above literature summary has been adapted from peer-reviewed scientific sources and organized to support qualified researchers evaluating BPC-157 in preclinical settings. Nordsci encourages all investigators to review the original journal articles referenced below for full experimental detail.
Predrag Sikiric, lead author of “Novel Cytoprotective Mediator, Stable Gastric Pentadecapeptide BPC 157. Vascular Recruitment and Gastrointestinal Tract Healing,” and co-author of “Stable gastric pentadecapeptide BPC 157 in honeybee (Apis mellifera) therapy, to control Nosema ceranae invasions in apiary conditions,” is a Professor in the Medical Department at the University of Zagreb. Predrag Sikiric is listed in [9] and [16] under the referenced citations.
Predrag Sikiric is referenced here as one of the leading scientists involved in the research and development of BPC-157. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Nordsci Peptides and this doctor. The purpose of citing the doctor is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying this peptide.
ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATONAL AND EDUCATIONAL PURPOSES ONLY.
The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: in glass) are performed outside of the body. These products are not medicines or drugs and have not been approved by the FDA to prevent, treat or cure any medical condition, ailment or disease. Bodily introduction of any kind into humans or animals is strictly forbidden by law.
